Entos Pharmaceuticals is pioneering advancements in genetic medicine through its proprietary Fusogenix™ PLV™ technology, which focuses on the safe and effective delivery of nucleic acid therapies. The Fusogenix PLV platform utilizes FAST fusion protein technology to facilitate direct fusion with cell membranes, allowing for the intracellular delivery of RNA and DNA therapies. This innovative approach bypasses traditional endocytosis mechanisms, enabling a more efficient and targeted delivery system that is non-liver tropic, meaning it can distribute therapeutic doses throughout various tissues and organs in the body. The platform is designed to be non-immunogenic, allowing for repeat dosing, which is crucial for long-term treatment strategies.

Additionally, Entos employs advanced targeting technologies such as FOCUS-AI and AIM to enhance the precision of its genetic therapies. The FOCUS-AI system utilizes artificial intelligence to optimize and customize formulations for specific cell and tissue targeting, while the AIM technology incorporates high selectivity ligands into the FAST proteins to improve targeting capabilities. This combination of innovative delivery mechanisms and precision targeting positions Entos Pharmaceuticals at the forefront of developing genetic cures for a range of diseases, including obesity, rare metabolic disorders, and various ocular and lung conditions.

Canada

Entos Pharmaceuticals Inc. is a clinical-stage genetic medicines company. A new reality in genetic medicine lies ahead, one that will be ushered in with the advent of safe, effective, and redosable nucleic acid delivery technologies. At Entos, we develop next generation genetic medicines using our proprietary Fusogenix proteolipid vehicle (PLV) drug delivery system. Fusogenix PLVs are formulated with FAST proteins to enable the delivery of nucleic acid into target cells through direct fusion.

Entos Pharmaceuticals

Company Details